Natalizumab for MS: New Guidelines, and Findings on Vision
One new report presents guidelines aimed at maximizing patient benefit and early identification of PML, and a second report describes the finding of reduction in subtle vision changes with natalizumab.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)